Clinical Applications of Bone Morphogenetic Proteins in Spine Surgery

Abstract

Dr. Koh is Assistant Professor, Department of Orthopaedic Surgery, University of Maryland, HSFII-S003, 20 Penn Street, Baltimore, MD 21201, E-mail: [email protected]; and Dr. Boden is Professor of Orthopaedic Surgery and Director, Emory Orthopaedics & Spine Center, Atlanta, GA. Dr. Koh and all staff in a position to control the content of this CME activity have disclosed that they and their spouses/life partners (if any) have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. Dr. Boden has disclosed that he receives royalties from Osteotech and that his spouse/life partner has no financial relationships with, or financial interests in, any commercial organizations related to this CME activity. The authors have disclosed that recombinant human bone morphogenetic protein–2 and osteogenic protein–1 have not been approved by the US Food and Drug Administration for use in spine surgery. Lippincott CME Institute, Inc., has identified and resolved all conflicts of interest related to this CME activity. Lippincott Continuing Medical Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 70% of the quiz questions correctly. This activity expires on September 30, 2011.